Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.lungcan.2008.04.010
DC FieldValue
dc.titleDistribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients
dc.contributor.authorSoo, R.A.
dc.contributor.authorWang, L.Z.
dc.contributor.authorYong, W.P.
dc.contributor.authorLee, S.C.
dc.contributor.authorTham, L.S.
dc.contributor.authorGoh, B.C.
dc.contributor.authorNg, S.S.
dc.contributor.authorChong, P.Y.
dc.contributor.authorSoong, R.
dc.contributor.authorLiu, J.J.
dc.contributor.authorLee, H.S.
dc.contributor.authorChoo, T.B.
dc.date.accessioned2011-09-29T06:43:00Z
dc.date.available2011-09-29T06:43:00Z
dc.date.issued2009
dc.identifier.citationSoo, R.A., Wang, L.Z., Yong, W.P., Lee, S.C., Tham, L.S., Goh, B.C., Ng, S.S., Chong, P.Y., Soong, R., Liu, J.J., Lee, H.S., Choo, T.B. (2009). Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 63 (1) : 121-127. ScholarBank@NUS Repository. https://doi.org/10.1016/j.lungcan.2008.04.010
dc.identifier.issn01695002
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/27416
dc.description.abstractObjective: Pharmacogenetics suggests variants of genes involved in gemcitabine pharmacology could be useful markers for predicting inter-ethnic and inter-patient outcomes from treatment with the agent. Here, we have characterized the distribution of variants of genes involved in gemcitabine pharmacology in ethnic Asian populations and their association with non-small cell lung cancer (NSCLC) patient outcome. Methods: All genes involved in gemcitabine transport, metabolism and activity were screened for suitable variants for analysis using publications and public databases. By pyrosequencing, the frequency of qualifying variants was characterized from germline DNA of 94 healthy Asian donors and 53 NSCLC patients receiving gemcitabine-based chemotherapy. Results: Significant differences in genotype distribution between Caucasians and Asians were seen at 10/25 (45%) variant loci. In NSCLC patients, CDA + 435 C > T variants were associated with response (p = 0.026) and time to progression (p = 0.016) and SLC28A1 + 1561 G > A variants were associated with neutropenia (p = 0.030) and thrombocytopenia nadir (p = 0.037). Conclusions: Many genotypes in gemcitabine pharmacology vary in their frequency between Caucasians and Asians. CDA + 435, and SLC28A1 + 1561 are worthy of further investigation as potential indicators of patient outcome after gemcitabine treatment. © 2008 Elsevier Ireland Ltd. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.lungcan.2008.04.010
dc.sourceScopus
dc.subjectEthnicity
dc.subjectGemcitabine
dc.subjectGene variants
dc.subjectNon-small cell lung cancer
dc.subjectPolymorphism
dc.typeArticle
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.contributor.departmentPHARMACOLOGY
dc.description.doi10.1016/j.lungcan.2008.04.010
dc.description.sourcetitleLung Cancer
dc.description.volume63
dc.description.issue1
dc.description.page121-127
dc.identifier.isiut000262812300021
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

52
checked on Apr 6, 2021

WEB OF SCIENCETM
Citations

45
checked on Apr 6, 2021

Page view(s)

284
checked on Mar 31, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.